PACIFIC-R is a real-world international observational study evaluating patients with unresectable stage III non-small-cell-lung cancer treated with durvalumab following platinum-based chemoradiation. At the annual BSMO meeting, baseline characteristics and progression-free survival results for the Belgian cohort of this study were presented and contextualised with the PACIFIC-R global population and the durvalumab arm of the phase III PACIFIC trial.
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
